STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo aims to shrink tough liver tumors
Disease control OngoingThis study is testing if a combination of two drugs, regorafenib and durvalumab, can shrink tumors in adults with high-risk liver cancer. The goal is to see if this treatment makes surgery more effective or possible. Patients receive the drugs for up to two years and are then mon…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Custom radiation doses aim to zap liver tumors more precisely
Disease control OngoingThis study is testing a more personalized way to deliver radiation treatment for advanced liver cancer that cannot be removed by surgery. Doctors aim to give a stronger, more precise dose of radiation directly to the tumor while trying to better protect the healthy parts of the l…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Scientists test radiation 'One-Two Punch' to rally Body's defenses against liver cancer
Disease control OngoingThis early-stage study is testing the safety and effectiveness of a two-step treatment for advanced liver cancer that cannot be surgically removed. First, patients receive a targeted radiation treatment directly to the liver tumor. Then, they receive two immunotherapy drugs desig…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug combo tested for Tough-to-Treat liver cancer
Disease control OngoingThis study is testing whether a new drug called pevonedistat can help control advanced bile duct cancer that starts in the liver. It is being tested alone and in combination with two standard chemotherapy drugs (carboplatin and paclitaxel) in about 40 patients whose cancer has wo…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC